Vivos Therapeutics, Inc., a company listed on the U.S. stock exchange, has experienced a significant change in its shareholder structure as reported in a recent filing with the Securities and Exchange Commission (SEC). The filing, an amended Schedule 13G/A, indicates that Ionic Ventures LLC, Ionic Management LLC, Brendan O'Neil, and Keith Coulston, collectively referred to as the Reporting Persons, have ceased to be the beneficial owners of more than five percent of Vivos Therapeutics' outstanding common stock. The amendment, dated September 30, 2024, updates the beneficial ownership information previously filed on September 24, 2024. The Reporting Persons now collectively own 83,000 shares, representing 1.8% of the company's common stock, based on 4,765,300 outstanding shares as reported in the company's prospectus supplement. This amendment serves as an exit filing for the Reporting Persons, indicating a reduction in their collective ownership stake below the five percent threshold that requires continued reporting under SEC rules.

Vivos Therapeutics, Inc., a company listed on the U.S. stock exchange, has experienced a significant change in its shareholder structure as reported in a recent filing with the Securities and Exchange Commission (SEC). The filing, an amended Schedule 13G/A, indicates that Ionic Ventures LLC, Ionic Management LLC, Brendan O'Neil, and Keith Coulston, collectively referred to as the Reporting Persons, have ceased to be the beneficial owners of more than five percent of Vivos Therapeutics' outstanding common stock. The amendment, dated September 30, 2024, updates the beneficial ownership information previously filed on September 24, 2024. The Reporting Persons now collectively own 83,000 shares, representing 1.8% of the company's common stock, based on 4,765,300 outstanding shares as reported in the company's prospectus supplement. This amendment serves as an exit filing for the Reporting Persons, indicating a reduction in their collective ownership stake below the five percent threshold that requires continued reporting under SEC rules.